Literature DB >> 31843464

Small molecules targeting HIF-1α pathway for cancer therapy in recent years.

Wendi Tang1, Guisen Zhao2.   

Abstract

Hypoxia is a very important feature of tumors, especially for solid tumors, and it was demonstrated highly relevant with aggressive biology, including anti-apoptosis, vasculogenesis and radiation or chemotherapy resistance. Correlatively, hypoxia-inducible factors 1-α (HIF-1α), which the wildest contribution of hypoxia-inducible factors (HIFs), plays a crucial role in the adaptation of tumor cells to hypoxia via upregulating the transcription of the oncogene and downregulating the transcription of suppressor gene. This review focus on the HIF-1α regulation including hydroxylation and acetylation, growth factors pathway, heat shock proteins(HSPs), and small molecule inhibitors for HIF-1α directly or indirectly.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HIF-1α; Hypoxia; Inhibitor

Mesh:

Substances:

Year:  2019        PMID: 31843464     DOI: 10.1016/j.bmc.2019.115235

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  11 in total

1.  Using mathematical modeling to estimate time-independent cancer chemotherapy efficacy parameters.

Authors:  Christine Pho; Madison Frieler; Giri R Akkaraju; Anton V Naumov; Hana M Dobrovolny
Journal:  In Silico Pharmacol       Date:  2021-12-05

2.  Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.

Authors:  Nicola Principe; Wayne J Aston; Danika E Hope; Caitlin M Tilsed; Scott A Fisher; Louis Boon; Ian M Dick; Wee Loong Chin; Alison M McDonnell; Anna K Nowak; Richard A Lake; Jonathan Chee; Willem Joost Lesterhuis
Journal:  Front Immunol       Date:  2022-05-11       Impact factor: 8.786

Review 3.  Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.

Authors:  Shweta Joshi; Andrew Sharabi
Journal:  Pharmacol Ther       Date:  2022-02-02       Impact factor: 13.400

Review 4.  The crosstalk between HIFs and mitochondrial dysfunctions in cancer development.

Authors:  Xingting Bao; Jinhua Zhang; Guomin Huang; Junfang Yan; Caipeng Xu; Zhihui Dou; Chao Sun; Hong Zhang
Journal:  Cell Death Dis       Date:  2021-02-26       Impact factor: 8.469

5.  Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy.

Authors:  Michael R Shurin; Viktor Umansky
Journal:  J Clin Invest       Date:  2022-05-02       Impact factor: 19.456

6.  DYRK1A suppression attenuates HIF‑1α accumulation and enhances the anti‑liver cancer effects of regorafenib and sorafenib under hypoxic conditions.

Authors:  Chong Zhang; Lin-Wen Wu; Zhi-Di Li; Man-Man Zhang; Jie Wu; Fei-Hua Du; Ling-Hui Zeng; Yang-Ling Li
Journal:  Int J Oncol       Date:  2022-03-04       Impact factor: 5.650

Review 7.  Nanomedicines for Overcoming Cancer Drug Resistance.

Authors:  Tingting Hu; Hanlin Gong; Jiayue Xu; Yuan Huang; Fengbo Wu; Zhiyao He
Journal:  Pharmaceutics       Date:  2022-08-01       Impact factor: 6.525

Review 8.  TGF-β signaling in the tumor metabolic microenvironment and targeted therapies.

Authors:  Xueke Shi; Jin Yang; Shuzhi Deng; Hongdan Xu; Deyang Wu; Qingxiang Zeng; Shimeng Wang; Tao Hu; Fanglong Wu; Hongmei Zhou
Journal:  J Hematol Oncol       Date:  2022-09-17       Impact factor: 23.168

Review 9.  Hypoxia/HIF Modulates Immune Responses.

Authors:  Yuling Chen; Timo Gaber
Journal:  Biomedicines       Date:  2021-03-05

10.  Nuclear scaffold protein p54nrb/NONO facilitates the hypoxia-enhanced progression of hepatocellular carcinoma.

Authors:  Mengqin Shen; Ruixue Zhang; Wenzhi Jia; Zongping Zhu; Xiaoping Zhao; Li Zhao; Gang Huang; Jianjun Liu
Journal:  Oncogene       Date:  2021-06-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.